Search results
Showing 481 to 495 of 1037 results for criteria
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
commissioned work. Your application will be reviewed against the eligibility criteria to ensure that you receive the appropriate level...
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of lungs for transplant. This involves using a machine to deliver an oxygenated solution to a donor lung and keep it at normal body temperature until it can be transplanted.
View recommendations for IPG695Show all sections
Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)
This framework sets out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA
paragraph 3.28 of the 2019 VS. They will operate in accordance with the criteria and terms set out in the 2014 PPRS, and guidance on our...
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)
Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.
Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
Digitally enabled therapies for adults with depression: early value assessment (HTE8)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....
Guidance on the use of liquid-based cytology for cervical screening (TA69)
Evidence-based recommendations on using liquid-based cytology for cervical screening in adults.
Evidence summaries: new medicines – Interim process statement (PMG1)
Evidence summaries: new medicines – Interim process statement
Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)
Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.
Early value assessment (EVA) guidance on artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referra...